Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment With a Bortezomib-based Regimen

Jingsong He, Xiaoyan Yue, Xiaoyan Han, Donghua He, Yi Zhao, Yang Yang, Gaofeng Zheng, Wenjun Wu, Zhen CaiResearch Square 2020 · DOI

Abstract

Background: It is very important to evaluate the prognosis of multiple myeloma (MM) patients before starting treatment. Although haematopoietic status may have a significant impact on patient survival, it has not received sufficient attention in current clinical practice.
Methods: This was a retrospective study of 150 newly diagnosed MM patients treated in one hematonosis treatment centre from May 2013 to June 2016, all of whom received first-line treatment with a bortezomib-based regimen. The effects of haematopoietic factors, including haemoglobin levels (Hgb <100 g/L), mean corpuscular volume (MCV >99.1 fL), and platelet count (<150 × 10E9/L), on the prognosis of the patients were analysed. Each of the above factors was assigned a value of 1 to generate a haematopoietic score.
Results: According to the results, 59 (39.3%) patients had a score of 0, 43 (28.7%) had a score of 1, 29 (19.3%) had a score of 2, and 19 (12.7%) had a score of 3. The median PFS times were 43.1, 24.5, 32.6 and 14.2 months, respectively (P<0.001), and the median OS times were NR, 47.1 months, NR and 31.4 months, respectively (P<0.001). Multivariable analysis showed that the R-ISS stage (3 vs 1-2, HR, 1.4), haematopoietic score (3 vs 0-2, HR, 1.91) and plasma cell percentage (>30%, HR, 1.96) are independent prognostic predictors for PFS; age (≤65 years, HR, 0.54), the Durie-Salmon stage (3B vs 1-3a, HR, 2.96), haematopoietic score (3 vs 0-2, HR, 2.53) and the bone marrow plasma cell percentage (>30%, HR, 2.35) are independent prognostic predictors of OS.
Conclusion: This study suggests that the haematopoietic score can be used to evaluate the prognosis of newly treated MM patients in the era of new drugs.

Introduction

Multiple Myeloma (MM) is a heterogeneous cancer of the plasma cells. While survival has improved significantly with the introduction of proteasome inhibitors like bortezomib, predicting an individual patient's trajectory remains challenging. Current gold-standard staging systems, like the Revised International Staging System (R-ISS), rely on serum albumin, β2-microglobulin, LDH levels, and chromosomal analysis. However, these systems do not always fully account for the "haematopoietic status"—the functional health of the bone marrow. This study introduces a simple three-point "haematopoietic score" to improve prognostic accuracy using routine blood work.

Methods and Datasets

The researchers conducted a retrospective study of 150 newly diagnosed MM patients at the First Affiliated Hospital of Zhejiang University School of Medicine. All patients received a bortezomib-based regimen as their first-line treatment. The study utilized a clinical dataset including routine blood counts, bone marrow plasma cell percentages, and cytogenetic results.

Table 1: Baseline characteristics of the 150 patients included in the study.

The Haematopoietic Score (0–3) was calculated by assigning one point for each of the following clinical thresholds met at diagnosis:

  1. Hemoglobin (Hgb): < 100 g/L (Anemia)
  2. Mean Corpuscular Volume (MCV): > 99.1 fL (Macrocytosis)
  3. Platelet Count (Plt): < 150 × 10⁹/L (Thrombocytopenia)

Key Results

The impact of the haematopoietic score on patient outcomes was significant across both Progression-Free Survival (PFS) and Overall Survival (OS). Patients with a score of 0 had a median PFS of 43.1 months, compared to just 14.2 months for those with a score of 3. Similarly, the median OS for patients with a score of 0 was "Not Reached," while patients with a score of 3 had a median OS of only 31.4 months.

Table 2: Univariable and multivariable analysis of prognostic factors for survival.

Multivariable analysis confirmed that the haematopoietic score is an independent predictor of survival. Even when accounting for R-ISS stage and age, a score of 3 carried a Hazard Ratio (HR) of 1.91 for PFS and 2.53 for OS compared to lower scores. Notably, MCV—a marker often overlooked in clinical practice—emerged as a significant independent predictor of poor outcomes when elevated.

Discussion and Conclusion

This study highlights the importance of the bone marrow "soil" in addition to the cancerous "seed." A high haematopoietic score suggests that the malignancy has significantly compromised the marrow's ability to produce healthy blood cells, leading to a poorer prognosis.

While the study is limited by its retrospective nature and sample size, the haematopoietic score offers a low-cost, easily accessible supplement to standard staging systems. Future work will focus on larger multi-center cohorts to validate these findings and explore the integration of this score with advanced cytogenetic data.

Summary updated

Abstract

<title>Abstract</title> <bold>Backgroud: </bold>It is very important to evaluate the prognosis of multiple myeloma (MM) patients before starting treatment. Although haematopoietic status may have a significant impact on patient survival, it has not received sufficient attention in current clinical practice.<bold>Methods:</bold>This was a retrospective study of 150 newly diagnosed MM patients treated in one hematonosis treatment centre from May 2013 to June 2016, all of whom received first-line treatment with a bortezomib-based regimen.The effects of haematopoietic factors, including haemoglobin levels (Hgb &lt;100 g/L), mean corpuscular volume (MCV&gt;99.1 fL), and platelet count (&lt;150 × 10E9/L), on the prognosis of the patients were analysed. Each of the above factors was assigned a value of 1 to generate a haematopoietic score.<bold>Results: </bold>According to the results, 59 (39.3%) patients had a score of 0, 43 (28.7%) had a score of 1, 29 (19.3%) had a score of 2, and 19 (12.7%) had a score of 3. The median PFS times were 43.1, 24.5, 32.6 and 14.2 months, respectively (P&lt;0.001), and the median OS times were NR, 47.1 months, NR and 31.4 months, respectively (P&lt;0.001). Multivariable analysis showed that the R-ISS stage (3 vs 1-2, HR, 1.4), haematopoietic score (3 vs 0-2, HR, 1.91) and plasma cell percentage (&gt;30%, HR, 1.96) are independent prognostic predictors for PFS; age (≤65 years, HR, 0.54), the Durie-Salmon stage (3B vs 1-3a, HR, 2.96), haematopoietic score (3 vs 0-2, HR, 2.53) and the bone marrow plasma cell percentage (&gt;30%, HR, 2.35) are independent prognostic predictors of OS. <bold>Conclusion: </bold>This study suggests that the haematopoietic score can be used to evaluate the prognosis of newly treated MM patients in the era of new drugs. However, there is still a need to enlarge the number of cases and carry out prospective research to validate this conclusion.
BibTeX
@inproceedings{he2020haematopoietic,
  author = {Jingsong He and Xiaoyan Yue and Xiaoyan Han and Donghua He and Yi Zhao and Yang Yang and Gaofeng Zheng and Wenjun Wu and Zhen Cai},
  title = {{Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment With a Bortezomib-based Regimen}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-35129/v1},
}
Figure